Pierre Geborek

affiliated with the university
More filtering options
  1. Acute alveolitis and sulphasalazine in rheumatoid arthritis

    Pierre Geborek, M Monti, F Sandblad & Frank Wollheim, 1984, In : Clinical and Experimental Rheumatology. 2, 3, p. 279-280

    Research output: Contribution to journalArticle

  2. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

    R. F. van Vollenhoven, S. Ernestam, Pierre Geborek, Ingemar Petersson, L. Coster, E. Waltbrand, A. Zickert, J. Theander, A. Thorner, H. Hellstrom, A. Teleman, C. Dackhammar, F. Akre, K Forslind, L. Ljung, R. Oding, A. Chatzidionysiou, M. Wornert & J. Bratt, 2009, In : The Lancet. 374, 9688, p. 459-466

    Research output: Contribution to journalArticle

  3. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas:relative risks and time-trends in the Swedish Biologics Register

    J Askling, E Baecklund, F Granath, Pierre Geborek, M. Fored, C Backlin, L Bertilsson, L Coster, L Jacobsson, S Rantapaa-Dahlqvist, Tore Saxne, R van Vollenhoven, L Klareskog & N Feltelius, 2009, In : Annals of the Rheumatic Diseases. 68, 5, p. 648-653 6 p.

    Research output: Contribution to journalArticle

  4. A survey of spinal collateral actions of feline ventral spinocerebellar tract neurons.

    Pierre Geborek, Elisabeth Nilsson, F Bolzoni & E Jankowska, 2012, In : European Journal of Neuroscience.

    Research output: Contribution to journalArticle

  5. Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof. Individuel monitorering af biotilgaengelighed og immunogenicitet-- sekundaerpublikation

    Klaus Bendtzen, Pierre Geborek, Morten Svenson, Lotta Larsson, Meliha C Kapetanovic & Tore Saxne, 2007, In : Ugeskrift for Laeger. 169, 5, p. 420-423

    Research output: Contribution to journalArticle

  6. Biological vs Conventional Combination Treatment and Work Loss in Early Rheumatoid Arthritis A Randomized Trial

    Jonas K. Eriksson, Martin Neovius, Johan Bratt, Ingemar Petersson, Ronald F. van Vollenhoven, Pierre Geborek & Sofia Ernestam, 2013, In : JAMA Internal Medicine. 173, 15, p. 1407-1414

    Research output: Contribution to journalArticle

  7. Brief report: enhancement of patient recruitment in rheumatoid arthritis clinical trials using a multi-biomarker disease activity score as an inclusion criterion.

    Ronald F van Vollenhoven, Rebecca Bolce, Karen Hambardzumyan, Saedis Saevarsdottir, Kristina Forslind, Ingemar Petersson, Eric H Sasso, C C Hwang, Oscar G Segurado & Pierre Geborek, 2015, In : Arthritis & Rheumatology. 67, 11, p. 2855-2860

    Research output: Contribution to journalArticle

  8. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.

    Alf Kastbom, Kristina Forslind, Sofia Ernestam, Pierre Geborek, Johan Karlsson, Ingemar Petersson, Saedis Saevarsdottir, Lars Klareskog, Ronald F van Vollenhoven & Karin Lundberg, 2016, In : Annals of the Rheumatic Diseases. 75, 2, p. 356-361

    Research output: Contribution to journalArticle

  9. Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis

    Pierre Geborek & Tore Saxne, 2000, In : Rheumatology. 39, 10, p. 1159-1161

    Research output: Contribution to journalArticle

  10. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival

    Irini Flouri, Theodora E. Markatseli, Paraskevi V. Voulgari, Kyriaki A. Boki, Ioannis Papadopoulos, Loukas Settas, Dimitrios Zisopoulos, Fotini N. Skopouli, Alexios Iliopoulos, George K. Bertsias, Pierre Geborek, Alexandros A. Drosos, Dimitrios T. Boumpas & Prodromos Sidiropoulos, 2014, In : Seminars in Arthritis and Rheumatism. 43, 4, p. 447-457

    Research output: Contribution to journalReview article

  11. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

    Ronald F. van Vollenhoven, Pierre Geborek, Kristina Forslind, Kristina Albertsson, Sofia Ernestam, Ingemar Petersson, Katerina Chatzidionysiou & Johan Bratt, 2012, In : The Lancet. 379, 9827, p. 1712-1720

    Research output: Contribution to journalArticle

  12. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment.

    Gisela Kobelt, Ingrid Lekander, Andrea Lang, Bernd Raffeiner, Costantino Botsios & Pierre Geborek, 2011, In : International Journal of Technology Assessment in Health Care. 27, 3, p. 193-200

    Research output: Contribution to journalArticle

  13. Costs in Relation to Disability, Disease Activity, and Health-related Quality of Life in Rheumatoid Arthritis: Observational Data from Southern Sweden

    JOHAN KARLSSON WALLMAN, Jonas K. Eriksson, Jan Åke Nilsson, Tor Olofsson, Lars Erik Kristensen, Martin Neovius & Pierre Geborek, 2016 Jul 1, In : Journal of Rheumatology. 43, 7, p. 1292-1299 8 p.

    Research output: Contribution to journalArticle

Previous 1 2 3 4 5 6 Next